Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology

Neurobiology of Disease

Volumn 43, Issue 3, 2011, Pages 598-608

  Reay, Daniel P ^b   Yang, Michele ^b,f   Watchko, Jon F ^c   Daood, Molly ^c   O'Day, Terrence L ^d   Rehman, Khaleel K ^b   Guttridge, Denis C ^e   Robbins, Paul D ^b   Clemens, Paula R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d MEDIMMUNE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f Children's Hospital Colorado   (United States)

Author keywords

Duchenne muscular dystrophy; Histopathology; Lengthening activation; Mdx mouse; Muscle necrosis; Muscle regeneration; NEMO binding domain peptide; NF B; Protein transduction domain; Specific force

Indexed keywords

I KAPPA B KINASE GAMMA BINDING DOMAIN PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DRUG EFFECT; DRUG SYNTHESIS; DUCHENNE MUSCULAR DYSTROPHY; EX VIVO STUDY; HINDLIMB; HISTOPATHOLOGY; IN VIVO STUDY; MOUSE; MUSCLE FORCE; MUSCLE FUNCTION; MUSCLE NECROSIS; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC THERAPY;

ANIMALS; DIAPHRAGM; DISEASE MODELS, ANIMAL; DYSTROPHIN; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NECROSIS; NERVE REGENERATION; NF-KAPPA B; PEPTIDES; PROTEIN STRUCTURE, TERTIARY;

EID: 79960273152     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.05.008     Document Type: Article

References (37)

1. Acharyya S., Villalta S.A., Bakkar N., Bupha-Intr T., Janssen P.M.L., Carathers M., et al. Interplay of IKK/NF-kappa B signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 2007, 117:889-901.
2. Bulfield, Siller W.G., Wight P.A., Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:1189-1192.
3. Dave S.H., Tilstra J.S., Matsuoka K., Li F., Karrasch T., Uno J.K., et al. Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J. Immunol. 2007, 179:7852-7859.
4. Di M.P., Ianaro A., Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum. 2005, 52:951-958.
5. Disatnik M.H., Dhawan J., Yu Y., Beal M.F., Whirl M.M., Franco A.A., et al. Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state. J. Neurol. Sci. 1998, 161:77-84.
6. Dogra C., Srivastava D.S., Kumar A. Protein-DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice. Mol. Cell. Biochem. 2008, 312:17-24.
7. Ervasti J., Campbell K. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 66:1121-1131.
8. Ervasti J., Ohlendieck K., Kahl S., Gaver M., Campbell K. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990, 345:315-319.
9. Grounds M.D., Torrisi J. Anti-TNF alpha (Remicade (R)) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 2004, 18:676-682.
10. Grounds M.D., Radley H.G., Lynch G.S., Nagaraju K., De L.A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol. Dis. 2008, 31:1-19.
11. Guttridge D. Signaling pathways weigh in on decisions to make or break skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7:443-450.
12. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999, 19:5785-5799.
13. Häcker H., Karin M. Regulation and function of IKK and IKK-related kinases. Sci. Signal. 2006, 357:1-19.
14. Hakansson S., Jacobs A., Caffrey M. Heparin binding by the HIV-1 tat protein transduction domain. Protein Sci. 2001, 10:2138-2139.
15. Hnia K., Hugon G., Rivier F., Masmoudi A., Mercier J., Mornet D. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient mdx mice. Am. J. Pathol. 2007, 170:633-643.
16. Jimi E., Aoki K., Saito H., D'Acquisto F., May M.J., Nakamura I., et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 2004, 10:617-624.
17. Khaja K., Robbins P. Comparison of functional protein transduction domains using the NEMO binding domain peptide. Pharmaceuticals 2010, 3:110-124.
18. Kumar A., Boriek A.M. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J. 2003, 17:386-396.
19. Lynch G.S., Rafael J.A., Hinkle R.T., Cole N.M., Chamberlain J.S., Faulkner J.A. Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. Am. J. Physiol. 1997, 272:C2063-C2068.
20. May M.J., D'Acquisto F., Madge L.A., Glockner J., Pober J.S., Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-1554.
21. Messina S., Seminara P., Aguennouz M., Monici M.C., Marini H., Squadrito F., et al. NF-kB blockade reduces skeletal muscle degeneration and enhances muscle function in mdx mice. Neuromuscul. Disord. 2004, 14:234-241.
22. Messina S., Altavilla D., Aguennouz M., Seminara P., Minutoli L., Monici M.C., et al. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am. J. Pathol. 2006, 168:918-926.
23. Mi Z., Mai J., Lu X., Robbins P.D. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol. Ther. 2000, 2:339-347.
24. Niebroj-Dobosz I., Fidzianska A., Glinka Z. Comparative studies of hind limb and diaphragm muscles of mdx mice. Basic Appl Myol. 1997, 7:381-386.
25. Nijboer C.H., Heijnen C.J., Groenendaal F., May M.J., van Bell F., Kavelaars A. Strong neuroprotection by inhibition of NF-kappaB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines. Stroke 2008, 39:2129-2137.
26. Noguchi H., Matsumoto S. Protein transduction technology: a novel therapeutic perspective. Acta Med. Okayama 2006, 60:1-11.
27. Rusnati M., Coltrini D., Oreste P., Zoppetti G., Albini A., Noonan D., et al. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J. Biol. Chem. 1997, 272:11313-11320.
28. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572.
29. Stedman H.H., Sweeney H.L., Shrager J.B., Maguire H.C., Panettieri R.A., Petrof B., et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352:536-539.
30. Strickland I., Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Ann. Rheum. Dis. 2006, 65:75-82.
31. Tilstra J., Rehman K.K., Hennon T., Plevy S.E., Clemens P., Robbins P.D. Protein transduction: identification, characterization and optimization. Biochem. Soc. Trans. 2007, 35:811-815.
32. Verma I. Nuclear factor (NF)-kappa B proteins: therapeutic targets. Ann. Rheum. Dis. 2004, 63:57-61.
33. Watchko J.F., Johnson B.D., Gosselin L.E., Prakash Y.S., Sieck G.C. Age-related differences in diaphragm muscle injury after lengthening activations. J. Appl. Physiol. 1994, 77:2125-2133.
34. Watchko J., O'Day T., Wang B., Zhou L., Tang Y., Li J., et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 2002, 13:1451-1460.
35. Whitehead N.P., Yeung E.W., Allen D.G. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin. Exp. Pharmacol. Physiol. 2006, 33:657-662.
36. Whitehead N.P., Pham C., Gervasio O.L., Allen D.G. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J. Physiol. 2008, 586:2003-2014.
37. Zubrzycka-Gaarn E.E., Bulman D.E., Karpati G., Burghes A.H., Belfall B., Klamut H.J., et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988, 333:466-469.